Hou, Jian Jin, Jie Xu, Yan Wu, Depei Ke, Xiaoyan Zhou, Daobin Lu, Jin Du, Xin Chen, Xiequn Li, Junmin Liu, Jing Gupta, Neeraj Hanley, Michael Li, Hongmei Hua, Zhaowei Wang, Bingxia Zhang, Xiaoquan Wang, Hui van de Velde, Helgi Richardson, Paul Moreau, Philippe Additional file 2: of Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study Supplementary results. Hou C16010 China Continuation study J Hematol Oncol. (DOCX 40 kb) China;Ixazomib;Multiple myeloma;Oral;Overall survival;Progression-free survival;Proteasome inhibitor;Relapsed/refractory 2017-07-06
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Randomized_double-blind_placebo-controlled_phase_III_study_of_ixazomib_plus_lenalidomide-dexamethasone_in_patients_with_relapsed_refractory_multiple_myeloma_China_Continuation_study/5182228
10.6084/m9.figshare.c.3820483_D2.v1